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Abstract: Primary psychosis, which includes schizophrenia and other psychoses not caused by other
psychic or physical conditions, has a strong impact worldwide in terms of disability, suffering and
costs. Consequently, improvement of strategies to reduce the incidence and to improve the prognosis
of this disorder is a current need. The purpose of this work is to review the current scientific literature
on the main risk and protective factors of primary psychosis and to examine the main models of
prevention, especially those related to the early detection of the onset. The conditions more strongly
associated with primary psychosis are socio-demographic and economic factors such as male gender,
birth in winter, ethnic minority, immigrant status, and difficult socio-economic conditions while the
best-established preventive factors are elevated socio-economic status and an economic well-being.
Risk and protective factors may be the targets for primordial, primary, and secondary preventive
strategies. Acting on modifiable factors may reduce the incidence of the disorder or postpone its
onset, while an early detection of the new cases enables a prompt treatment and a consequential
better prognosis. According to this evidence, the study of the determinants of primary psychosis
has a pivotal role in designing and promoting preventive policies aimed at reducing the burden of
disability and suffering of the disorder.
Keywords: schizophrenia; prodromal stage; risk stratification; onset; early detection; prevention;
incidence; duration of illness (DOI); duration of untreated psychosis (DUP); prognosis
1. Introduction
Primary psychosis is a heterogeneous group of mental disorders that includes various
diagnoses characterized by positive symptoms (i.e., delusions and/or hallucinations),
disorganized thinking and/or motor behavior, and negative symptoms (i.e., affective
blunting, alogia, asociality, anhedonia, and avolition) [1]. The term primary indicates
that these disorders are not secondary to the effects of a psychoactive drug (substance or
medication) or to another pathological condition (e.g., neoplasia, autoimmune disease,
depression, mania) [1]. Two main diagnostic systems are employed in psychiatry: the
Diagnostic and Statistical Manual of mental disorders, 5th edition [2] and the International
Classification of Diseases 11th Revision [3]. Both include diagnoses that meet the above-
mentioned diagnostic criteria for primary psychosis. In the DSM-5 [2] these diagnoses
are schizophrenia, schizophreniform disorder, brief psychotic disorder, schizoaffective
disorder, delusional disorder, other specified schizophrenia spectrum and other psychotic
disorder, and unspecified schizophrenia spectrum and other psychotic disorder, while in the
ICD-11 [3] schizophrenia, acute and transient psychotic disorder, schizoaffective disorder,
delusional disorder, and other primary psychotic disorder. The lifetime prevalence primary
psychosis is around 1.94% [4] and schizophrenia, the most prevalent disorder of this group
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of diagnoses, is the 19th disease in terms of years lived with disability in both genders
worldwide [5].
The onset of primary psychosis usually occurs in adolescence or early adulthood and
men are more often diagnosed earlier than women: 18–25 years old men and 25–35 years
old women [6]. The onset can be preceded by premorbid developmental alterations and can
start with a prodromal phase characterized initially by non-specific symptoms and then by
subthreshold positive, negative, affective, and behavioral symptoms. The prodromal phase
can be absent or not identifiable. Then, the first expression of psychotic symptoms appears,
followed by an increase in characteristic symptoms resulting in a definite diagnosis of
primary psychosis [1]. According to the speed of appearance of psychotic symptoms, three
modes of onset of primary psychosis have been identified: acute (psychotic symptoms
appear from few hours to one month), gradual (from one to six months), and insidious
(more than six months) [7].
A correct and early diagnosis is necessary in order to set up appropriate treatments
promptly and thus to reduce the duration of untreated psychosis (DUP). This a key point
in the treatment of primary psychosis, as a shorter DUP has been associated with improved
prognosis in terms of less severe positive, negative, and global psychopathological symp-
toms, a higher chance of remission, and a higher overall functioning [8–10]. In addition, a
longer duration of illness (DOI), defined as the time elapsed since the onset of prodromal
symptoms, is associated with poorer treatment response, higher suicidal risk, and lower
social functioning [11]. Therefore, acting in order to postpone the onset of the prodromal
phase, thus shortening the DOI, could improve the prognosis of primary psychosis. Given
the necessity to reduce the burden of disability related to primary psychosis, an imple-
mentation of preventive strategies in this field is needed. One possible way to achieve this
is to focus on the study of the trajectories that leads to primary psychosis. Even though
little is clearly known about the etiology and pathophysiology of the disorder, a wide
field of the scientific literature has studied possible determinants of primary psychosis in
terms of statistical association, namely risk and protective factors. The in-depth knowledge
of these determinants can be employed to implement prevention programs and health
promotion. Indeed, acting on modifiable risk and protective factors with prevention and
health promotion policies might help to reduce the disability, economic, and emotional
burden of primary psychosis. This could happen in two ways: on the one hand, it might
reduce or delay the onset of the disorder, thus decreasing lifetime prevalence and the DOI;
on the other hand, it enables to formulate risk algorithms to identify promptly new cases
of primary psychosis, hence reducing the DUP.
In light of this, the purpose of this work is to review the main and most up-to-date
scientific evidence on the risk and protective factors for the development of primary
psychosis by evaluating them as possible targets or instruments for prevention and early
detection of the onset.
Considering the objective of the present review, the main hypothesis underlying
is that a deeper knowledge of risk and protective factors in this field may broaden the
understanding of the mechanisms that lead to primary psychosis, allowing in this way to
carry out more aware, targeted and effective preventive policies.
2. Methods
We searched the Web of Knowledge database (incorporating Web of Science and MED-
LINE) using the following search string: ((((TI = (“protective factors”)) AND TI = (psychosis))
OR (TI = (“protective factors”)) AND TI = (schizophrenia)) OR (TI = (“risk factors”)) AND
TI = (schizophrenia)) OR (TI = (“risk factors”)) AND TI = (psychosis) OR ((((TI = (“pre-
vention”)) AND TI = (psychosis)) OR (TI = (“prevention”)) AND TI = (schizophrenia)) OR
(TI = (“detection”)) AND TI = (schizophrenia)) OR (TI = (“detection”)) AND TI = (psychosis).
We selected papers published from 1980 and 16 August 2021. No proximity searches nor
hyphen were employed. All kind of articles were included in the research, even if mainly
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second literature publications (reviews, systematic reviews, meta-analyses, umbrella reviews
and meta-umbrella reviews). Original articles were included in two cases:
(i) they were very recent and were not cited in second literature publications;
(ii) They discussed topics never included into second literature works, mainly regarding
protective factors or preventive programs that have a less wide literature.
We excluded original articles and reviews/meta-analyses/systematic reviews if al-
ready comprised is systematic syntheses like umbrella and meta-umbrella reviews, unpub-
lished works (e.g., posters) and publications written in a language other than English and
German for the second part. The selection process is shown in Figure 1.
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Figure 1. PRISMA flow-chart. * No automation tools were used. From: The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews [12].
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We divided this narrative review into the following two parts: a description of risk
and protective factors for primary psychosis and a discussion on the potential role of these
determinants in prevention strategies, particularly in the early detection of the onset.
The choice to discuss both risk and protective factors and early detection of the onset
of primary psychosis is motivated by the fact that risk and protective factors could allow
an earlier identification of subjects with primary psychosis (secondary prevention) and that
policies aimed at enhancing the disorder’s prognosis act at the level of risk and protective
factors themselves (primordial and primary prevention). However, in scientific literature
the two topics are often discussed separately, so we decided to structure results section in
two separate parts, in order to improve the clarity of the text.
3. Results
3.1. Risk Factors for Primary Psychosis
According to the WHO definition, a risk factor is a determinant, namely any attribute,
characteristic, or exposure that increases the likelihood of developing a disease, in this case
primary psychosis, at an individual level. Risk factors can be divided into genetic and
environmental factors. As for many other chronic diseases, genetic and environmental risk
factors combine with each other increasing the likelihood of developing primary psychosis.
In particular, gene-environment (GE) interplay can be classified into GE interaction (GxE)
and GE correlation (rGE). GE will be used to indicate a general interplay between genetic
and environmental factors, GxE to describe a random relationship, and rGE a non-random
interaction where the presence of a specific genetic factor increases the likelihood of being
exposed to a specific environmental determinant. rGE can be passive (e.g., the association
between genetic factors transmitted by the parents to the offspring and an abusive home
environment that can traumatize the offspring itself), evocative (e.g., genetic factors can
lead to childhood anxiety disorders and consequently to social rejection trauma) and active
(e.g., genetic factors can facilitate the use of cannabis) [13].
Thus far, it is not possible to address genetic risk factors in the offspring; however,
some environmental risk factors are modifiable and offer the opportunity to act on them in
terms of prevention. A determinant that can be modified by intervention, thereby reducing
the probability of occurrence of disease or other outcomes (e.g., delay the onset) may be
referred to as a modifiable risk factor, and logically must be a cause of the disease [14].
On the contrary, an attribute that that can be used as an indicator of increased risk of
developing a disease but is not necessarily a causal factor is referred to as risk marker.
In primary psychosis, risk markers are usually the result of different interacting genetic
and environmental risk factors. Some examples are ultra-high-risk state, ethnicity, and
immigration status [15].
In the next two sub-sections, we will present the main risk and protective factors
for the development of primary psychosis. To improve expository clarity and facilitate
the reading of this review, we will present the risk factors as part of two main categories:
individual and environmental factors. This is an arbitrary distinction in which individual
factors represent family or constitutive characteristics of the subject while environmental
factors represent exposure to specific events or conditions. Genetic factors are part of the
individual category.
3.1.1. Individual Risk Factors
Familiar and Parental Risk Factors
Family history is considered one of the strongest risk factors for primary psychosis [16],
with a heritability (i.e., the degree to which a phenotype, in this case a disorder, is geneti-
cally determined, calculated by regression-correlation analyses among close relatives) of
schizophrenia estimated around 79–81% and a similar proportion in other disorders of
the spectrum [17,18]. In particular, for close biologic relatives of patients with schizophre-
nia [13,19,20] was demonstrated a 7.5-fold higher risk for the development of primary
psychosis [21] and studies on monozygotic twins [13,19,20] showed a concordance rate of
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approximately 50% [20,22]. Other familiar risk factors for primary psychosis are a mother
affected by primary psychosis, or a mood disorder, or any severe psychiatric condition or a
father affected by any severe psychiatric condition [23].
Regarding parental factors, one of the most studied factors is parental age at the
time of the birth of the children with a higher risk of developing primary psychosis in
the offspring for maternal age <20 years or >30 years and a further risk for women with
>35 years of age [23]. Similar associations were found for paternal age <20 years [15,23]
and >35 years [23,24], with evidence of an increased risk for >45-years-old fathers [15].
Other parental factors associated with an increased o risk of developing primary psychosis
are maternal pre-pregnancy obesity [15] or hypertension [23] and having more than three
previous pregnancies [23], and low paternal socio-economic status [13,15].
Sociodemographic Risk Factors
Among all socio-demographic factors, it is well known that male individuals [15,20]
with an age between 15 and 35 years [15] are at increased risk of developing psychosis.
Moreover, being part of a disadvantage group and having a low socioeconomic status are
two other risks factors for primary psychosis, as confirmed by different studies [13,15].
The season of birth is an additional important factor affecting the risk of psychosis [13].
In particular, winter season of birth [20,23] and winter/spring season of birth in Northern
hemisphere [15,23,24] have been found to be strongly associated with an increased risk of
developing primary psychosis. This risk appears to become stronger with the increase of
latitude and the severity of winter [20]. However, the mechanism underneath is not totally
understood, but it has been suggested that it relates to higher rates of prenatal infections
and malnutrition [20].
Ethnicity represents one of the most implicated variables in the onset of primary
psychosis. The concept of ethnicity includes two dimensions: having an immigrant status
and belonging to a specific ethnic minority [15,24]. Both of these aspects may be better
defined as risk markers as they may be the result of different interacting risk factors (e.g.,
racism, minority stress, isolation, low economic status etc.). In particular, the migrant
status itself contributes to the pathogenesis of psychosis [13,15,20,24], mostly in second-
generation immigrants [15,24]. For instance, being a Black-Caribbean ethnicity in England
has the strongest statistical association [15,24], while other minorities like North African
immigrants in Europe [15,24] and Black African and Asian ethnicity in England [15] showed
weaker evidence. Different studies showed that migrants with black skin color might share
a common risk exposure, possibly because of a genetic vulnerability background or for
factors connected to ethnic disadvantage and lower socioeconomic status [25].
Finally, another important aspect in the development of primary psychosis is urban-
icity: higher rates of psychotic disorders have been found in densely populated areas,
suggesting that urban environments increase the risk of primary psychosis [13,15,20,24,26].
Urbanicity as well can be considered a risk marker as it acts through the interplay of
multiple factors like deficit of green spaces, marginalization, and poor social network, as
compared to rural areas [26]. Surprisingly, though, the effect of urbanicity does not seem to
be widely mediated by pollution [27].
Personal Pre-Morbid Characteristics Associated with a Higher Risk of Developing
Primary Psychosis
The following characteristics or conditions at birth have been associated with a higher
risk of developing primary psychosis: premature birth [13,23]; use of incubator or resusci-
tation [15]; birth weight <2000 g [15], <2500 g [15,23], <2999 g [23], with an increased risk
in terms of higher odd ratio (OR) for lower weights [13]; birth length less than 49 cm [23];
being small for gestational age [23]; and low or high levels of neonatal vitamin D [15].
Moreover, several secondary literature studies (e.g., umbrella reviews, meta-analyses)
provided sufficient evidence about atypical developmental characteristics and a higher risk
of developing primary psychosis. In particular, strong evidence was reported about minor
physical defects [15,24]. Focusing on neurodevelopment, extra-cranial size, non-right hand-
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edness [15,24] and early life alterations in motor, cognitive, and language evolution seem
to be associated with a higher risk of developing schizophrenia [28]. In particular, delay
in walking unsupported [15,24], and pre-onset motor function alterations [15], showed
some evidence regarding their role in increasing the risk of primary psychosis, however
larger studies are required to confirm these associations. Focusing on intelligence, it has
been identified a negative linear relationship between premorbid IQ deficit and the risk of
developing schizophrenia [15,24,28], as for every 1-point decrease in premorbid IQ matches
a 3.7% increase in risk of developing primary psychosis. In addition, greater IQ deficits are
associated with an earlier illness onset [28].
As regards personality, many personality characteristics have been found to be im-
plicated in the risk of developing primary psychosis, even though the majority of them
showed a weak statistical association [15,16,24]. In particular, novelty seeking, harm
avoidance, self-transcendence [15,24] and neuroticism [15,16] seem to increase the risk of
developing primary psychosis, even if researchers agree that the most implied personality
aspect is trait anhedonia [15,24].
Comorbidities Associated with a Higher Risk of Developing Primary Psychosis
Two groups of disorders appear to be more related to the onset of primary psychosis:
autoimmune illnesses and psychiatric conditions.
Focusing on the first group, there is an amount of evidence supporting the link be-
tween immunological processes and psychosis. Elevated levels of inflammatory markers,
especially in childhood and adolescence, might increase the risk of primary psychosis. In
addition, both primary psychosis and autoimmune diseases often show a relapse-remitting
course of illness where recurrences are characterized by increments of peripheral inflamma-
tory markers. Moreover, a family history of autoimmune disease seems to increase the risk
of schizophrenia and associations with psychotic disorders have been found for several
autoimmune diseases [29]. This link might be explained by an aberrant inflammatory
response due to an immunogenetic predisposition that facilitate both autoimmune diseases
and primary psychosis (e.g., common MCH genes) [29,30].
The vast majority of autoimmune diseases (e.g., multiple sclerosis [29], Systemic Lupus
Erythematosus [29,31], autoimmune thyroid disorders like Grave’s disease [29–31], autoim-
mune encephalitis N-methyl-D-aspartate receptor–(NMDAR) antibody mediated [29,31],
autoimmune hepatitis, Crohn’s disease, diabetes mellitus type 1, psoriasis and Guillain-
Barre syndrome) can cause neuropsychiatric symptoms, including psychotic ones, with
a direct pathophysiological mechanism. In these cases, psychosis can be considered sec-
ondary to autoimmune diseases themselves, which consequently cannot represent an actual
risk factor for primary psychosis. On the other hand, some studies found that few autoim-
mune diseases could actually arise the risk of primary psychosis without a clear direct
action on the CNS. Celiac disease seems to be associated with the risk of schizophrenia,
since populations with smaller consumption of wheat seem to have lower incidence rates
of schizophrenia, and gluten-free diet had positive effects on psychotic symptoms [29,30].
In addition, pernicious anemia and pemphigoid reached significant evidence regarding
their role in increasing the risk of developing primary psychosis [30].
Regarding psychiatric comorbidities, a recent study found that premorbid eating
disorders are common in people that will develop primary psychosis. Compared with
patients without a history of eating disorders, these patients with primary psychosis present
specific phenotypic features, that is female sex, higher IQ and more severe psychotic
symptoms [32].
Other known psychiatric conditions associated with primary psychosis are Obsessive-
compulsive disorder (OCD) and obsessive-compulsive symptoms (OCS). In particular,
there is some evidence implying that a diagnosis of OCD may be associated with elevated
risk for future development of primary psychosis and that OCD and OCS influence the
course of the psychotic disorder [33].
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Finally, schizotypal personality disorder seems to lie on a continuum with schizophre-
nia spectrum disorders and to represent a plausible factor somehow linked to primary
psychosis [34–36]. The disorders seem to have a significant overlap in terms of etiology, as
regards genetic, biological, and psychosocial factors [37].
Genetic Factors Associated with a Higher Risk of Developing Primary Psychosis
Currently, primary psychosis, in particular schizophrenia, is considered polygenic
and multifactorial disorders. People with primary psychosis often present multiple genetic
polymorphisms quite frequent in the general population, each of which contributes a small
effect to disease susceptibility. About this topic, in the last years, research focused on the
identification of common genetic variants that play a role in the development of primary
psychosis. However, despite genetics accounts for about 80% of the liability, no gene seems
to be sufficient or necessary for the development of the disease [20].
Recently, due to the complex genetic architecture of primary psychosis and to the
evolution of biotechnology, the focus has shifted from single genes studies to genome-wide
scale (Genome Wide Association Studies—GWAS). For example, the study conducted
by the Schizophrenia Working Group identified more than 100 independent loci asso-
ciated with schizophrenia [38], suggesting that these variants contribute to the genetic
susceptibility for primary psychosis [13]. Simultaneously, the detection of chromoso-
mal rearrangements pointed out the implication of copy number variants—CNVs, small
insertions and deletions (indels), as for the 22q11.2 microdeletion syndrome [31,39–41].
Compared to single CNVs and indels, a smaller contribution to the risk of developing pri-
mary psychosis was found for each single nucleotide variation—SNV [17,19,39]. CNVs and
indels are unique and rare in the general population. Instead, common in individuals with
neurodevelopment disorders, including primary psychosis [17,40]. In fact, approximately
2.5% of schizophrenia cases have a known CNV [40], suggesting that these specific genetic
variants might take part in the pathogenesis of primary psychosis.
The possible role of the product of gene loci associated with a higher risk of developing
primary psychosis are described in Table 1 [17,18,22,42,43]. Genes were grouped according
to the main function of their product.
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The genes presented are among the most studied and reported in different meta-analyses or systematic reviews [17,18,22,42,43]. To facilitate
consultation of the table, we have divided these genes in relation to their structure, localization, and main function (first column). The last
three columns summarize functions synoptically. The nomenclature, the description of the products of the genes and their function is that
proposed by GeneCards® [47]. Specific references for the function of single genes are reported in the table.
It should also be emphasized that some genetic variants are implicated in increasing
the risk of psychosis not only for themselves but also mainly through the association with
certain environmental risk factors. For example, specific genetic variants of the Catechol-O-
Methyltransferase (COMT) increase the risk of developing primary psychosis mainly in
subjects exposed to childhood trauma or stress. Other similar GE interplay are those of
FK Binding Protein Prolyl Isomerase 5 (FKBP5) and childhood trauma, AKT-8 retrovirus
Serine/Threonine Kinase 1 (AKT1) and cannabis use, and Catenin Alpha 3 (CTNNA3) and
cytomegalovirus infection in utero [13].
At last, some evidence supported the role in the pathogenesis of primary psychosis
of specific gene variants coding for molecules related to the functioning of the immune
system. In particular, alterations in neuroinflammatory pathway like microglial activation
are associated with primary psychosis [17]. On a molecular level, these processes are
mainly supported by imbalance in inflammatory cytokines (altered signaling of interleukin
1 beta-IL-1B—and increased levels of IL-6) and alterations in the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) signaling [17]. Moreover, focusing on adaptive
immunity, the most studied loci in primary psychosis, especially in schizophrenia, are
HLA- A, B, and C of the antigen-presenting Major Histocompatibility Complex (MHC),
Class I and HLA-DRB1 and DQB1 of the MHC, Class II. Many different variants of these
loci were associated with the diagnosis of a primary psychosis [17,19].
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3.1.2. Environmental Risk Factors
Prenatal and Perinatal Risk Factors
Prenatal and perinatal environment, and consequently insults, is largely implicated
in the etiopathogenesis of primary psychosis, even though its specific contribution re-
mains unclear [23]. Recent meta-analyses and umbrella reviews have revealed that sev-
eral pregnancy-related and perinatal risk factors are significantly associated with psy-
chosis [13,15,23,24,48], suggesting the possible role of suboptimal number of antenatal
care visits on mother’s mental health [23]. Obstetric complications represent some of the
most studied and most consistently implicated environmental risk factors. Among them,
worth mentioning are diabetes or obesity during pregnancy [15]; emergency caesarean
section [15]; threatened premature delivery [15]; uterine atony [15]; unspecified obstetric
complications [13,15,23,24]; antepartum hemorrhage [15,23]; hypoxia [23]; preterm rup-
tured membranes [23]; polyhydramnios [23]; HSV type 2, Toxoplasma gondii or other
unspecified maternal infections [13,23,48], especially during the second trimester [48];
maternal anemia [13]; maternal stress not otherwise specified [13,23]; maternal nutritional
deficits [13,23]; asphyxia during delivery [23].
In addition, Ursini et al. [49] pointed out that the interactions between some set of
genes that participate in the cellular stress response and are selectively expressed in the
placenta and the exposure of specific intra-uterine complications (e.g., prenatal infection)
may increase the risk of developing primary psychosis. The Authors suggest that this
adverse prenatal GE interplay could negatively influence placental transcriptome and thus
placental functioning and fetal development. This vulnerability is higher for male fetuses.
In terms of pre and perinatal risk factors, it has been suggested that the activation of
the immune system, through oxidative stress and neuroinflammation, could mediate their
effects on psychotic risk, supporting the abnormal neurodevelopment. In fact, subjects
exposed to high inflammation in utero are at an increased risk of developing schizophrenia
in the future [13]. In particular, N-methyl-D-aspartate receptors (NMDAR) located in
a subpopulation of cortical parvalbumin-containing interneurons (PVIs) might be more
sensitive to neuroinflammation during the perinatal and pubertal periods, resulting in a
hypofunction and in a synaptic alteration [50].
Childhood-Related Environmental Risk Factors
In the last decades, early traumas have reached a particular research interest in
mental health. In particular, trauma models of mental disorders have highlighted the
effect of different kinds of stress during the early stages of life as key factors in the future
development of psychiatric conditions [51].
Focusing on the risk of developing primary psychosis, strong evidence has been
found about childhood adversities and traumas in general [24,51]. Childhood adver-
sities include child maltreatment (sexual, physical and emotional/psychological abuse,
neglect) [13,15,52–54], peer victimization (in particular bullying) [13,52,53], both active and
passive [55], parental death [52,53], and parental separation [55].
Only parental death appears to be independently associated with augmented primary
psychosis risk [52]. The other factors seem to interact with each other and with other
variables such as age, frequency and duration of the exposure to the traumas in determining
the increment of the risk. In this view, increasing attention has been paid to dose-response
effects of trauma. With regard to these aspects, it should be stressed that these types of
risk factors tend to add to each other as being exposed to one type of traumatizing event
actually increases the risk of being expose to another [53].
Focusing on the GE interplay of early life traumas, different studies reported an rGE
correlation showing that the offspring of a parent affected by psychosis is more prone to be
exposed to dysfunctional elements of the family environment, as in the case of parental
communication deviance [16]. Moreover, the effect of childhood trauma in increasing
the risk or psychosis has been found to be partially independent from a previous genetic
susceptibility [56]. One possible mechanism underlying this partial independence of the
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environmental factors from the genetic ones is the epigenetic impact of childhood traumas
on gene expression profile, in particular through altered global DNA mutilation [57].
According to this explanation, there would be no need of an alteration of the DNA sequence
for a variation of gene expression such that a phenotype of primary psychosis emerges, as
epigenetic effects of traumas would be sufficient by themselves.
Another risk factor to be considered is the exposure to infections during childhood,
suggesting that the period of vulnerability to infections is not confined to the prenatal one.
Viral infections involving central nervous system (CNS) are associated with a higher risk
of subsequent psychosis [28,31,58]. Moreover subjects with multiple hospitalizations for
infections have a higher risk of developing psychosis [58]. Two main hypotheses have been
proposed to explain this relationship, that are a direct and an indirect brain damage. The
first is directly caused by the pathogen, while the second one is mediated by a dysfunctional
activation of the immune system in the CNS after the pathogen stimulus [58]. Following
this latter hypothesis, besides CNS infections, other infections (e.g., Toxoplasma gondii
IgG+, Toxocara spp, Chlamydia psittaci, Human endogenous retrovirus type W, Chlamydia
pneumoniae, Borna disease virus, Human Herpes Virus type 2), occurring after birth and
before the onset of psychotic symptoms, represent risk factors for psychosis [15,24].
Adolescence-Related Environmental Risk Factors
Environmental risk factors associated with primary psychosis that occur later in
development, usually during adolescence, are mostly substance use-related [13,20].
In particular, cannabis use has been strongly associated with primary psy-
chosis [20,24,56,59,60]. Cannabis users have an increased risk of developing schizophre-
nia [13], proportionally to the cumulative amount consumed [13,59,61]. In addition,
cannabis abuse is associated with an earlier onset of the disorder [56]. Another factor
influencing the risk related to cannabis abuse is the age of onset of cannabis consumption,
as early consumption, particularly before 15 years of age, results in a greater likelihood of
developing primary psychosis during adulthood [61]. This association between cannabis
use and risk of developing primary psychosis can be another example of a GE interplay; in
fact, the presence of a specific polymorphism in the COMT gene, which reduces the activity
of the enzyme, increases the risk of developing primary psychosis in cannabis users [61].
Other substances associated with the development of psychosis are psychostimulants.
The abuse of these drugs (above all cocaine and amphetamines) is usually associated
with acute psychosis, with a four-time increased risk; furthermore, subjects with a family
history of psychiatric illness that abuse psychostimulants appear to be more susceptible to
persistent psychotic symptoms. Moreover, this connection between psychostimulants and
risk of psychosis can be also applied to children with a family history of mental disorders
taking these drugs to treat attention-deficit/hyperactivity disorder (ADHD) [13].
Tobacco as well could take part in psychosis risk [13,15,24,62] with a 2-fold increase
in risk of schizophrenia or other schizophrenia spectrum disorders and a dose-response
mechanism [63]. The mechanism underlying this association is not clear, with some
hypotheses in favor of an rGE correlation where a genetic arrangement that favors the
development of primary psychosis also favors tobacco smoking for attenuating a specific
distress that manifests in the prodromal phase of the disorder. In any case, a clear causal
link between cigarette smoking and the development of primary psychosis has not yet
been established.
Finally, among substance abuse, alcohol is well known to be associated with neu-
ropsychiatric consequences, including delirium tremens, alcohol-related brain damage,
Korsakoff’s syndrome and alcoholic hallucinosis [64]; meanwhile individuals with psy-
chotic disorders, in particular schizohrenia or schizoaffective disorder, have a three times
increased risk of severe alcohol use [65,66], link which is partially explained by a shared
genetic liability [67].
In contrast to other substances listed before which have evidence in increasing risk of
primary psychosis, in literature there are no findings about a similar role of alcohol or its
Diagnostics 2021, 11, 2146 13 of 27
role in transition to psychosis in clinical high-risk patients [68], even if secondary psychotic
symptoms are relatively frequent.
In addition, some studies highlighted a possible link between maternal alcohol use
during pregnancy and different psychopathological outcomes in the offspring, including
primary psychosis [69,70], but no statistically significative association has been found
so far.
Continuous Risk Factors and Factors That Can Play a Role at Any Time in Life
As regards environmental pollutants, there is evidence that exposure to benzene [15],
xenobiotic heavy metals (e.g., lead and cadmium), nitrogen and sulfur oxides, organic solvents,
and other components of may increase the risk of developing primary psychosis [13,71]. The
neurobiological mechanism underlying this connection is not clearly known.
Traumatic brain injury can play a role in facilitating the onset of primary psychosis at
any time in life [13,15,72]. In this case, the two main mechanisms proposed to explain this
connection are that the permanent damage caused by the trauma alters the CNS, favoring
the onset of the disorder and that subjects with schizophrenia prodromes may be more
exposed and sensitive to accidents [72].
Finally, considering that last years’ SARS-CoV-2 pandemic, some studies have investi-
gated the relationship between COVID-19 respiratory infection and the onset of psychosis.
The results have been summarized in a meta-analysis by Watson et al. [73], which showed
that infected patients can present a range of neuropsychiatric symptoms but did not find any
significant strong association between the SARS-CoV-2 infection and primary psychosis.
3.2. Protective Factors for Primary Psychosis
Protective factors have been defined as “those factors that modify, ameliorate or alter
a person’s response to some environmental hazard that predisposes to a maladaptive
outcome” [74]. Regarding their role, they do not necessarily promote normal evolution in
the absence of risk factors, but they may make a remarkable difference in the influence of
risk factors [75]. Notably, a positive environment might play a role in protecting genetically
susceptible individuals, especially during the vulnerable adolescence period [16].
Compared to risk factors, relatively few studies concerning protective factors for
primary psychosis have been carried out during the years.
As for the previous discussion about risk factors, we will present protective factors as
part of two main categories: individual and environmental factors.
3.2.1. Individual Protective Factors
Parental, Socio-Demographic, and Personal Protective Factors
Regarding maternal protective factors, worth mentioning are maternal age between
20–29 years and maternal nulliparity [23].
Some socio-demographic factors are implied in protecting from the risk of developing
psychosis, like an age >35 years and an elevated socio-economic status [15].
Among personal physical characteristics, also, in this case, birthweight plays a
part as higher birthweight, in particular if >3500 g [23], represent a protective factor
against psychosis.
Furthermore, higher olfactory identification abilities seem to be protective against psy-
chosis [15,24]. This connection is motivated by the fact that in patients with schizophrenia
have been observed important olfactory deficits in different olfactory tasks, in particular,
odor memory and identification. This is a result of a dysfunction in the peripheral and
central olfactory system, i.e., the primary olfactory cortex. This alteration may also involve
other brain regions associated with the pathophysiology of the disorder, like the temporal
lobe [76]. These olfactory deficits have not exceeded the statistical threshold to be consid-
ered valid risk factors for the development of primary psychosis [15,24]. On the contrary,
however, more developed olfactory abilities seem to protect from the disorder [15,24].
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As mentioned above, premorbid IQ plays a role in the pathogenesis of primary
psychosis. It has been observed that individuals with low or average IQ were at significantly
increased risk of developing schizophrenia than those with higher IQ, suggesting the active
and protective role of cognitive reserve in primary psychosis [24,28], even in case of 12-
years old subjects with a positive family history for psychosis [77].
The role of personality in psychopathology has long been explored and some person-
ality traits, such as extraversion, openness, agreeableness, and conscientiousness have been
found to be negatively associated with psychosis [15,16].
Even though resilience is a heterogeneous concept difficult to assess, it is clear that it
is a quality that contributes to positive adaptation to significant adversities and demand-
ing ambient [16,78]. Resilience in some high-risk individuals appeared to be protective
against developing schizophrenia, but the reason remains unknown and needs further
investigations [78].
Autoimmune Comorbidities Associated with a Reduced Risk of Developing Primary Psychosis
Regarding general comorbidities, among autoimmune disorders, recent research
has found significant negative associations between rheumatoid arthritis [29,30,79] and
ankylosing spondylitis [29,30] and primary psychosis.
Due to the late onset of rheumatoid arthritis, is has been suggested that this relation-
ship can be partly explained by an under-diagnosis, caused by a limited life expectancy
and worse health care in individuals with psychosis [30]. However, a specific MHC class II
DRB1 gene variant, namely the HLA-DRB1*04, has been associated with both an increased
risk of rheumatoid arthritis and a reduced risk of developing schizophrenia [17,18,30],
suggesting that a common immunogenetic background may promote the autoimmune
disorder and protects from the mental one.
As concerns ankylosing spondylitis, the age of onset is far earlier, so that the under-
diagnosis explanation due to the age of onset of the autoimmune disease in relation to
that of primary psychosis cannot be given. Moreover, apparently, the two disorders do not
seem to share a clear common immunogenetic profile; therefore, further investigations are
needed [30].
3.2.2. Environmental Protective Factors
Prenatal Protective Factors
As nutritional deprivation during pregnancy has been found to increase risk of psy-
chosis, as well as an adequate prenatal nutrition, are essential to satisfying the increased
nutrient demand and guarantee a normal fetal development [80]. In this context, prenatal
dietary supplementation with vitamin D, iron and folates [80], or phosphatidyl-choline [81]
seem to help preventing psychosis onset.
Furthermore, a recent study pointed out that individuals exposed to elevated maternal
levels of anti-inflammatory cytokines whose production was stimulated by T helper 2
lymphocytes in utero, were significantly less prone to evolve in psychosis in adulthood [82].
Childhood and Adolescence-Related Environmental Protective Factors
The role of family environment is implicated also in protecting against the onset of
psychosis. Strong evidence has been reported about its protective role. In particular a
family with four children or less, with two or more years difference between them, a good
parental system, clear boundaries within the family and healthy relationships with relatives
appear to be protective against primary psychosis [16]. A more positive atmosphere at
home [83,84], the perception of an elevated social support among 18-years-old people with
mothers with psychosis-spectrum disorder [77] and a greater neighborhood social cohesion
among children of mothers with a psychosis-spectrum disorder [77] were found to be
protective against the psychosis onset in the offspring in that defined group of patients.
Living in a stimulating family environment and in a cohesive community were found
to be protective factors against primary psychosis [16], even among children exposed to
Diagnostics 2021, 11, 2146 15 of 27
poly-victimizations, while social support and living in a cohesive community are protective
for poly-victimized adolescents [83].
Finally, among studies on adopted individuals, healthy patterns of baby growth [85]
and a healthy and great communication between adopting parents and children [86] reduce
the risk of primary psychosis in subjects at high genetic risk for schizophrenia.
A recent meta-analysis of Brokmeier et al. [87] analyzed the role of physical activity as
a risk or protective factor in incidence of psychosis. A more frequent physical activity is
associated with a 27% decreased risk of psychosis, though the sample size was limited, so
this result should be confirmed by larger studies.
A summary of risk and protective factors and markers, divided according to the phase
of occurrence and their putative role in preventive strategies is shown in Table 2.
Table 2. Risk and protective factors of primary psychosis.














Family history of primary psychosis • +++ [13,16,17,19–21] No -
Paternal characteristics (e.g., age <20 or >45, low
socio-economic status) • +++
[13,15,23,
24] No -
Maternal characteristics (e.g., age <20 or >35, any severe
psychiatric condition, pre-pregnancy obesity) • +++ [15,23]
Only
obesity Primary
Diabetes and hypertension during pregnancy • ++ [15] Yes Primary
Maternal infections during pregnancy • +++ [13,23,48] Yes Primary
Suboptimal number of antenatal care visits • ++ [23] Yes Primary
Maternal stress during pregnancy • +++ [13,23] Yes Primordial a
Maternal nutritional deficits during pregnancy • +++ [13,23] Yes Primary
Obstetric complications (e.g., maternal or fetal hypoxia
during delivery, preterm ruptured membranes) • +++ [15,23] No -
Neonatal factors (e.g., premature birth, incubator or
resuscitation) • +++ [13,15,23] No -
Minor physical anomalies • ++++ [15,16,24,28] No -
Genetic factors (cf. Table 2) • • • +++ [17,18,22,42,43] No -
Socio-demographic (e.g., male gender, ethnic minority, birth






Childhood adversities and traumas (e.g., physical,




Difficult parental relationship (e.g., parental communication
deviance, separation or death, neglect) • +++
[15,52,53,
55] Only some Primordial
c
Childhood infections (mostly CNS infections) • +++ [15,24,28,31,58] Yes Primary
Traumatic brain injury • • ++ [13,15] Yes Primary
Exposure to traffic • • ++ [15] Yes Primordial




Tobacco use • ++ [13,15,24,62] Yes
Primary/
Secondary
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Table 2. Cont.














Cannabis use • +++ [13,20,24,56,59,60] Yes
Primary/
Secondary
Psychostimulants use • ++ [13,20] Yes Primary/Secondary
Autoimmune diseases (e.g., celiac disease, pernicious anemia) • • ++ [29,30] No -
Psychological characteristics (e.g., trait anhedonia; premorbid
low IQ) • • ++++ [15,24] No -
Other psychiatric disorders (e.g., obsessive compulsive
disorder, schizotypal personality) • ++ [32–37] Yes Primary
Urbanicity * • • +++ [13,15,20,24,26] No -
Ethnicity (migration and specific ethnic minorities) * • • ++++ [15,24] No -
Prenatal dietary supplementation (vitamin D, iron, folates,
phosphatidyl-choline) • ++ [80,81] Yes Primary
d
Socio-demographic (e.g., elevated socio-economic status and
an economic well-being) • • • • +++ [15] Yes Primordial
Physical characteristics (e.g.,: olfactory identification abilities) • • ++ [15,24] No -
Psychological characteristics (e.g., extraversion, openness;
high premorbid IQ; resilience) • • ++ [16,24,28] No -
Positive family environment (e.g., good parental system,
healthy relationships with relatives) • • ++ [16,83,84] Yes Primordial








Physical activity • + [87] Yes Primordial/Primary
The number of plus signs denotes the strength of evidence for the association. This number was chosen qualitatively according to the
following logic: ++++ indicates very high or high evidence levels reported in meta-analytic umbrella reviews included in this review;
+++ indicates consistent evidence reported in multiple large-scale studies or a meta-analysis included in this review; ++ indicates evidence
reported in a single meta-analysis included in this review; + indicates evidence reported in a single study, multiple small/low-quality
studies, or few studies with conflicting reports included in this review. The strength of the association (e.g., odd ratios, relative risks)
reported in the studies mentioned was not reported in the present table. • indicates the period of life (i.e., prenatal, perinatal, childhood,
adolescence) during which risk or protective factors contribute to the development of primary psychosis. NA: not available as we did not
find any study that directly analyzed the effect of reducing a risk factor or promoting a protective factor on the development of primary
psychosis. * risk marker; a effective preventive strategies; b effective preventive strategies [88,89]; c effective preventive strategies [90];
d effective preventive strategies [80,81].
3.3. Early Detection of the Onset
The onset of psychosis can be defined as an acute phase crisis characterized by florid
and sustained psychotic symptoms (delusions and/or hallucinations), lasting at least four
weeks [91]. Over the past two decades, increasing efforts have been made to detect early
the onset of psychosis to minimize the DUP and improve clinical outcomes. This leads to
preventive strategies with the aim to postpone and promptly detect the onset. In order to
achieve this goal, it is necessary to identify populations at risk and stratify the risk through
apposite tools in order to carry out targeted interventions. In accordance with this, we will
present the main populations at risk, the tools used for the stratification of the risk itself,
and possible models of preventive interventions.
3.3.1. Help Seekers and Populations at Risk of Developing Primary Psychosis
In the context of the general population, where the lifetime risk of developing schizophre-
nia is about 1%, it is possible to find individuals seeking help at early detection services.
The so-called “help-seekers” usually have been exposed to multiple risk factors and have
an increased risk of developing primary psychosis. However, only a 20–30% of these
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subjects meets the criteria for the Clinical High Risk for Psychosis (CHR-P) state, defined by
the concomitance of certain risk factors, a functional impairment, and possible associated
attenuated psychotic symptoms [92]. In any case, a follow-up for help-seekers is required
as the CHR-P subpopulation has a 20% risk of developing psychosis in 2 years (first episode
of psychosis or persistent attenuated psychotic syndrome) while another 60–70% of the
help-seekers will face another psychiatric disorder (e.g., bipolar disorders, major depressive
disorder, substance use disorders, personality disorders etc. [92,93]
Moreover, among CHR-P subjects has been identified a further subgroup called Ultra
High Risk (UHR), whose criteria currently require to have had one of this conditions:
attenuated psychotic symptoms during the past year (APS); brief, limited or intermittent
psychotic symptoms (BLIPS), not lasted longer than a week and spontaneously remitted; a
first degree relative affected by a psychotic disorder or a schizotypal personality disorder,
associated with a significant functional impairment during the previous year [94]. The
transition rate to full-blown psychosis of these subjects was estimated at around 30% in
two years [95].
3.3.2. Screening Tools for Stratification of the Risk of Developing Primary Psychosis
Several kinds of instruments have been proposed to enhance prediction of psychosis
onset in the CHR-P population. In particular, different clinical screening questionnaire
have been suggested such as the Prodromal Questionnaire [96], which focuses on the
prodromal phase, and the Clinical High At Risk Mental State (CHARMS) developed by
McGorry et al. [93]. The risk calculator developed by Cannon et al. [97] and the trans-
diagnostic risk calculator by Fusar-Poli et al. [98], though, are screening based on risk
identification approaches. Two main instruments for clinical translation of neuroimaging
(PSYSCAN) and prognostic (PRONIA) information were also proposed [93]. In addition,
probabilistic multimodal models combining different domains, that are patient history, clin-
ical assessments, and biomarkers (e.g., neuroimaging, cognitive, and molecular markers),
were also introduced to assess the risk of transition to overt primary psychosis [99,100].
The most known example is the model suggested by Clark and colleagues [99].
In addition, for the same purpose of risk stratification, in the last few years efforts have
been made to take advantage of new technologies in order to improve the detection of new
cases and the access to mental health (e.g., use of virtual reality, forum, online platforms,
and mobile app specifically designed to identify risk factors and symptoms) [101,102].
These types of interventions, even promising, require more studies to be validated for the
clinical practice.
3.3.3. Models and Levels of Preventive Interventions and their Limitation
Universal prevention at the level of general population promotes some pharmacolog-
ical and psychosocial interventions acting on some well-known modifiable risk factors:
perinatal administration of phosphatidylcholine and N-acetylcysteine to support brain de-
velopment and anti-inflammatory neuroprotection; lifetime supplementation with omega-3
fatty acid, vitamins, sulforaphane and prebiotics to reduce neuroinflammation and enhance
good mental health; school-based behavioral interventions to lower the risk of bullying and
substance abuse; physical exercise to support cognitive functioning through improvement
of neuronal plasticity [90].
Another level of prevention targets specific groups of individuals, whose risk of devel-
oping a mental disorder is significantly higher than the rest of the population, presenting
an accumulation of risk factors. In these cases, school-based mental health assistance,
assertiveness training, and stress and anxiety management have the greatest chance to
prevent maladaptive behavior and symptomatic manifestations [90].
Anyway, nowadays the most employed preventive approach [94,103], focuses on
subjects during prodromal stage, i.e., individual with CHR-P with the purpose to alter the
trajectory of mental disorders, delaying the onset of first episode of psychosis, increasing
the chance of better long-term outcomes, reducing unnecessary suffering caused by the
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delay of the intervention, and bettering engagement with services [103]. Therefore, enor-
mous progress has been made in this field, and specific services have been implemented
worldwide (Early intervention for psychosis services—EIS), targeted at young CHR/UHR
people and their families [101,104].
Once identified CHR-P individuals, it is firstly indicated a primary prevention by the
use of needs-based and psychological interventions (cognitive behavioral therapy—CBT
or integrated psychosocial interventions, such as psychoeducation, social skills training,
metacognitive training, cognitive remediation, and family therapy), that need to be charac-
terized in the light of personal characteristics, risk profile (severity of attenuated positive
and negative symptoms and level of functioning), preferences of the single subject [105].
Psychosocial interventions may be effective in decreasing vulnerability to psychosis; in
fact, they increase coping mechanisms and lower vulnerability to stressors, improving self-
confidence, self-esteem, cognitive abilities, social skills, social network, and support [106].
Among all interventions in reducing risk for transition in FEP at 12 and 18 months,
Cognitive Behavioral therapy (CBT) showed the strongest level of evidence, being effective
in restoring thoughts and changing behaviors that maintain symptomatology and distress,
while other types of interventions, even promising, require more clinical trials [107]. Addi-
tionally, it is important to treat potential other comorbid psychiatric disorders following
actual guidelines and aim to improve recovery and quality of life [105].
Although antipsychotic medications represent the indicated treatment for first episode
psychosis (FEP), they are currently suggested in the prodromal phase of the illness only
for specific complex cases (i.e., attenuated psychotic symptoms with an impact on global
functioning and quality of life) and only for some low-dose atypical antipsychotics (mostly
amisulpride), due to several potential side effects and to the lack of sound evidence of their
effectiveness in preventing psychosis [106].
Antidepressant treatment is not indicated in FEP, even if there is some evidence that it
might be successful in delaying the onset of psychosis, by treating depressive prodromal
symptoms, as well as the use of anxiolytics may postpone psychosis [106].
Finally, there is some suggestion that CHR-P subjects may benefit from taking omega-3
polyunsaturated fatty acids (PUFAs), reducing the risk of transition to psychosis [106].
In addition to the mentioned established treatments historically used in CHR-P states,
new recent advancements are under development and validation. Examples are exercise,
smartphone applications, virtual reality, brain stimulation, social media, biofeedback,
oxytocin-based interventions, mindfulness-based interventions, sleep hygiene, intervention
enhancing protective factors, intervention eliminating barriers to health care, intervention
reducing stigma, and mental health prevention in urban planning [102]. Nevertheless,
studies regarding these recent research developments are still ongoing and it is necessary to
wait for the results to have sufficient evidence and establish whether they could represent
valid new treatment instruments.
Despite the fact that recent studies have focused mainly on interventions during
clinical high risk and prodromal stages [105,106], prospects of primary intervention are
often limited by costs, practicability [108] and actual usefulness, due to the limited detection
rate of the total onset (approximately 5%) [90].
3.3.4. Integrated Model of Prevention and Early Detection of the Onset in Primary Psychosis
Greater hopes rest on preventive early interventions on the first episode of psychosis,
aiming to postpone psychosis onset, reduce the duration of DUP, improve treatment re-
sponse, well-being, functioning and social skills, and prevent disease progression [92].
Nevertheless, currently there is a lack of screening tools for the early identification of
the onset of psychosis. The actual used psychopathological early recognition instru-
ments (e.g., BSABS—Bonn Scale for the Assessment of Basic Symptoms [109], CAARMS—
Comprehensive Assessment of At-Risk Mental States [110], SIPS—Structured Interview for
Prodromal Syndromes [111]) mainly focused on assessing clinical symptoms. A particularly
interesting instrument is the Early Recognition Inventory for the retrospective assessment
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of the Onset (ERIraos) Checklist, developed by Hafner and collaborators [112–114]. This
is a two-step early recognition inventory, practical and sufficiently valid instrument to be
used at a non-specialist primary care level, with good psychometric properties, meant for
the early detection of UHR subjects and of patients with untreated illness, to assess the
likelihood of psychosis onset. It is divided into two parts:
(i) a first part, the ERIraos-Check List, which is used for screening purposes, contains
questions on generic and psychotic psychiatric symptoms, on global functioning,
with importance given to self-perception of functioning, and on the evaluation of
some well-known risk factors for primary psychosis such as obstetric complications,
neurodevelopment delays or alterations, family history, and substance abuse;
(ii) a second part, the ERIraos-Symptom List, which is administered to people evaluated
at least at modest risk of transition to psychosis in the ERIraos-Check List. This
second-level evaluation is carried out in specialized centers and aims to carefully
detect imminent transition [115]. Thereafter, the ERIraos has been successfully em-
ployed as a tool for the early recognition of psychosis risk in several further German
studies [116–118] and subsequently translated and validated into different languages
and populations [115,119]. This instrument proved to be suitable for routine use as a
scale for the identification of the at-risk subjects.
Past strategies have been mostly based on finding programs and instruments designed
to reduce the DUP [120–122]. For this purpose, a better collaboration between primary
care services and specialist mental health services, which follow “consultation-liaison” and
“collaborative care” models are needed to bring diagnostic tools in the context of primary
care and create an integrated model of detection and prevention of primary psychosis [90].
An example of this strategy is the one carried out by Hafner et al. [108]. They suggested
focusing on the estimated 70% of individuals with a DUP longer than one year, promoting
in Germany a specific multi-step approach. First, at primary care centers they used the
ERIraos Check List to identify subjects at risk of developing primary psychosis. These
at-risk subjects were subsequently referred to an early-intervention center for a detailed
risk assessment using the ERIraos Symptom List. This second assessment provided two
risk profiles:
(i) subjects at early (pre-psychotic) prodromal stage and
(ii) subjects at late (early psychotic) prodromal stage.
For the treatment part of the project, subjects at early prodromal stage were random-
ized to cognitive behavioral psychotherapy (CBT) or usual clinical management, while
those at late prodromal stage were randomized to antipsychotic treatment with amisulpride
or usual clinical management. The work of Hafner and colleagues [108] represented an
important pilot integrated approach, which evidenced promising even though limited
results [123], but most of all prepared the ground for future similar integrated programs.
4. Discussion
As highlighted in the previous sections of this work, the risk and protective factors for
the development of primary psychosis can be divided into modifiable and non-modifiable
factors and risk factors proper and risk markers. Modifiable risk and protective factors
allow to act on the incidence and prevalence of the disorder, those that cannot be modified
and risk markers are useful for the stratification of the risk of developing primary psychosis
and therefore for the design of screening tools.
By acting on the modifiable factors that can actually influence the risk of developing
primary psychosis, the incidence of the disorder can be reduced. These preventive inter-
ventions aimed at reducing incidence belong to primordial and primary prevention [14].
Similarly, acting on modifiable risk and preventive factors at a stage closer to the onset of
primary psychosis the onset itself may be delayed, thus resulting in a reduction of the DOI.
Through risk stratification and early identification of the onset, it will be possible to carry
out a prompt and adequate treatment, thus reducing the DUP. This type of preventive
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interventions that can improve the prognosis of the disorder through the reduction of DOI
and DUP belong to secondary prevention strategies [14].
All these preventive interventions have positive effects in terms of reduction of the
burden of suffering and disability of the disorder and may improve the quality of life of
patients with primary psychosis and their caregivers (Figure 2).




Figure 2. Interplay between risk and protective factors, prevention, early detection of the onset, and outcomes. DOI: du-
ration of illness; DUP: duration of untreated psychosis. The figure shows how acting on risk and protective factors through 
prevention (horizontal arrow) and through an early detection of the onset (vertical arrow), is it possible to reduce the 
incidence, the DOI and the DUP of primary psychosis. This allows ameliorating the prognosis and lowering the global 
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upstream of risk and protective factors and concern environmental, economic, social, be-
havioral, and cultural aspects of a given population [14]. Primordial preventive interven-
tions are implemented through health and social policies that cover large parts of the gen-
eral population and could be designed by public health policy makers in collaboration 
with mental health experts who can provide specific and targeted skills to act effectively 
on remote determinants of psychiatric disorders. In our research, we have not found sci-
entific publications that have studied the impact of primordial prevention policies on the 
development of primary psychosis. However, policies of this kind are generally desirable 
for the prevention of all major and most disabling mental disorders.  
In the second case, we found interventions that target more specific modifiable risk 
and protective factors in specific subgroups of the population, and they are usually re-
ferred as primary preventive inventions [14]. They are also implemented on relatively 
large portions of the general population and aim to reduce risk factors and enforce pre-
ventive ones through public health and health promotion interventions [14]. Unlike pri-
mordial prevention policies, they act more specifically on certain factors that are plausibly 
linked to the pathogenesis of a disorder [14]. As shown above, many studies have vali-
dated the role of certain risk factors in aiding the onset of the disorder, but little is known 
about the effectiveness of policies to reduce them. Few studies evaluated the effectiveness 
of prenatal and early infancy preventive programs on specific risk factors [88,89]. In par-
ticular, nursing home visits to expectant mothers and their families in difficult social cir-
cumstances [88] and educational interventions performed at school and at home to teach 
useful tools to support low-income families and their preschool children [89] were able to 
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DOI: duration of illness; DUP: duration of untreated psychosis. The figure shows how acting on risk and protective
factors through prevention (horizontal arrow) and through an early detection of the onset (vertical arrow), is it possible to
reduce the incidence, the DOI and the DUP of primary psychosis. This allows ameliorating the prognosis and lowering the
global burden of disability of the disease (not shown).
This is possible by implementing preventive and health promotion actions that reduce
risk factors or promote protective ones. Such interventions may be broad-based and
relevant for the general population, or more targeted and useful for specific subgroups of
the population that may benefit from them.
In the first case, i.e., broad-based interventions, fall primordial preventive strategies
aimed at promoting physical and mental health by acting on health determinants that
are upstream of risk and protective factors and concern environmental, economic, social,
behavioral, and cultural aspects of a given population [14]. Primordial preventive inter-
ventions are implemented through health and social policies that cover large parts of the
general population and could be designed by public health policy makers in collaboration
with mental health experts who can provide specific and targeted skills to act effectively
on remote determinants of psychiatric disorders. In our research, we have not found
scientific publications that have studied the impact of primordial prevention policies on the
development of primary psychosis. However, policies of this kind are generally desirable
for the prevention of all major and most disabling mental disorders.
In the second case, we found interventions that target more specific modifiable risk
and protective factors in specific subgroups of the population, and they are usually referred
as primary preventive inventions [14]. They are also implemented on relatively large
portions of the general population and aim to reduce risk factors and enforce preventive
ones through public health and health promotion interventions [14]. Unlike primordial
prevention policies, they act more specifically on certain factors that are plausibly linked
to the pathogenesis of a disorder [14]. As shown above, many studies have validated the
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role of certain risk factors in aiding the onset of the disorder, but little is known about the
effectiveness of policies to reduce them. Few studies evaluated the effectiveness of prenatal
and early infancy preventive programs on specific risk factors [88,89]. In particular, nursing
home visits to expectant mothers and their families in difficult social circumstances [88] and
educational interventions performed at school and at home to teach useful tools to support
low-income families and their preschool children [89] were able to reduce child abuse,
neglect, and difficult socioeconomic situations through a more profitable use of the welfare
system [88–90]. Regarding protective factors, by their nature more difficult to investigate
and validate from a methodological point of view, the available scientific evidence is
much less as compared to the one on risk factors. However, health promotion policies
aimed at implementing protective factors of resilience and resistance to the development
of mental disorders appear to have had positive effects. An example is that of supportive
interventions for mothers with primary psychosis [90]. Such intervention would have
been able to reduce the incidence of primary psychosis in the offspring compared to
families with equal family vulnerability who had not benefited from this specific health
promotion intervention.
Regarding secondary prevention, which focuses on delaying the onset of the disorder
and treating it early, the scientific evidence accumulated to date mainly concerns the
study of risk and protective factors with the aim of identifying populations at risk of
developing primary psychosis. The rationale for such strategies is to carry out screening
programs targeted at restricted segments of the general population where the risk of
developing full-blown psychosis within two years is quite high (20–30%). Follow-up
on risk subjects enables, on the one hand, to perform policies to reduce risk factors (for
example, discouraging the use of cannabinoids) and to promote protective factors (for
example, by carrying out targeted psychotherapies) within targeted subpopulations and
on the other hand to early detect the onset of the disorder by reducing the DUP. As regards
the identification of risk subjects, targeted screening tools have been developed which
consider both risk factors and markers, and both modifiable and not modifiable factors.
In this case, in fact, the aim is the stratification of the risk in order to make more useful,
efficient and less expensive the identification and follow-up of risk subjects. This enables to
include risk markers, not necessarily related to the etiology of the disorder, and protective
and risk factors not modifiable because, in this case, there are no interventions to act on
these factors. It has been demonstrated that screening policies on the general population
are not cost/benefit effective. On the contrary, targeted screening gives good results
on subpopulation at risk of developing primary psychosis. However, the proportion of
primary psychosis with an unexpected onset remains very high and only 5% of total onset
of primary psychosis is detected with specific screening programs [90]. For this reason,
it is necessary, on the one hand, to refine screening methods and, on the other hand, to
maintain active early intervention strategies for early treatment of the onset with effective
and evidence-based therapies as soon as possible. To do this, a model is needed that
integrates primary care and specialized psychiatric care such as that proposed by Hafner
and collaborators and described in the result section [108].
Finally, some studies have shown how to act on the risk and protective factors in
clinical high-risk groups brings good results in terms of reduction and delay in incidence
and better prognosis after the onset. However, again, numerous other studies on large
samples are needed.
The main limitation of the present work is the absence of critical appraisal of the
selected papers, as no quality tools were employed in the selection process. This may have
biased the selection of scientific work included.
5. Conclusions
In conclusion, we can affirm that the study of risk and preventive factors has a
central role in improving the early detection of the onset of primary psychosis. It is also
crucial for the study of the etiopathogenesis of the disorder and for the implementation
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of health prevention and health promotion policies that reduce incidence, prevalence and
consequently the burden of disability and suffering related to primary psychosis. The study
and the knowledge of risk and preventive factors allow the implementation of primordial
and primary preventive interventions aimed at reducing risk factors and encouraging
protective factors. Preventive interventions, in terms of secondary prevention, allow early
detection of the onset of primary psychosis. Overall, prevention and early detection of
the onset have positive outcomes including a reduction of the incidence rate of primary
psychosis, of the DOI, consequently to the delayed incidence, and of the DUP as a result of
prompt interventions at the onset of the disorder. This leads to a prognosis improvement
and to a reduction of the burden of disease in terms of disability and suffering for patients
and caregivers.
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